Personalis Inc. (PSNL)
NASDAQ: PSNLHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PSNL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.55B
- EPS (TTM)
- -$1.16
- Dividend yield
- None
- 52-week range
- 4.96 – 18.89
- Day range
- 14.23 – 14.67
- Volume / Avg
- 3.34M / 2.49M
- Beta
- —
- Shares outstanding
- 108.40M
52-week range
PSNL stock today
On Nov 20, PSNL ended the session at $14.27, shedding $0.45 (3.06%), versus the S&P 500's 3.70% decline. Shares are 24.5% below their 52-week high of $18.89, set on Aug 21, 2026 and 188.0% above the 52-week low of $4.96, in the middle of the past year's range. PSNL is up 79.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 46.7%.
Personalis has posted a net loss over the last twelve months (EPS of -$1.16), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Personalis
Company profilePersonalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Christopher M. Hall
- Headquarters
- Fremont, CA
- Employees
- 259
- IPO year
- 2019
- Website
- personalis.com
Financial highlights
Full financialsIn fiscal 2025, Personalis generated $69.6 million in revenue, down 17.7% from fiscal 2024, its first annual decline since 2022. Personalis reported a net loss of $81.3 million, compared with a loss of $81.3 million a year earlier. Gross margin was 22.7% (down from 31.7%) and operating margin -126.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $69.65M | $84.61M | $73.48M | $65.05M | $85.49M |
| Growth | -17.69% | +15.15% | +12.97% | -23.92% | +8.70% |
| Net income | $-81.27M | $-81.28M | $-108.30M | $-113.31M | $-65.23M |
| EPS (diluted) | $-0.91 | $-1.37 | $-2.25 | $-2.48 | $-1.49 |
Analyst forecast
ForecastConsensus (5 analysts)
hold
Avg. price target
$15.17+6.31%
- Strong buy 0
- Buy 1
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.32 vs —
PSNL news
All PSNL news- Personalis, Inc. Reports Q3 Clinical Test Volume of 13,157 and Overall Revenue of $25.6 millionNasdaq
- Personalis GAAP EPS of -$0.32 misses by $0.07, revenue of $25.59M beats by $4.24MSeeking Alpha
- Personalis Reports Third Quarter ResultsBusiness Wire
- PSNL Shareholder Notice: Personalis $16.25 per Share Merger Under Investigation on Behalf of ShareholdersPR Newswire
- PSNL Investor Investigation: Personalis Shareholders Are Alerted to the Pending Investigation into the $16.25 per Share MergerPR Newswire
- Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, ToastSeeking AlphaCRWV, PSNL
- Noteworthy ETF Outflows: ARKG, TXG, PSNL, GHNasdaqARKG, TXG, PSNL, GH
- Tempus AI Acquires Personalis: Why Both Stocks Are A Buy NowSeeking AlphaTEM, PSNL
Personalis peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TRUPTrupanion Inc. | 35.56 | -0.86% | $1.54B | vs PSNL |
| LMRILumexa Imaging Holdings Inc. | 14.26 | +1.42% | $1.37B | vs PSNL |
| ALHCAlignment Healthcare Inc. | 6.37 | -2.00% | $1.33B | vs PSNL |
| FTREFortrea Holdings Inc. | 18.55 | -7.94% | $1.79B | vs PSNL |
| CLOVClover Health Investments Corp. Class A | 3.73 | -1.06% | $2.00B | vs PSNL |
| VCYTVeracyte Inc. | 25.13 | +0.36% | $2.03B | vs PSNL |
| FRNMFreenome Inc. | 9.36 | -5.69% | $1.04B | vs PSNL |
| CSTLCastle Biosciences Inc. | 32.86 | -1.63% | $1.01B | vs PSNL |
Indexes, lists and sector
Personalis stock FAQ
What is Personalis's stock price today?
PSNL last traded at $14.27 as of Nov 20, 4:00 PM EST, down 3.06% on the day. Prices are delayed at least 15 minutes.
Who is Personalis's CEO?
Mr. Christopher M. Hall is the chief executive officer of Personalis Inc., which has about 259 employees.
What is the PSNL 52-week high?
The 52-week high for PSNL is $18.89 and the 52-week low is $4.96. The stock is currently 24.5% below its high.